John V. Oyler co-founded BeiGene in 2010. He has served as CEO and a member of the Board of Directors from the company’s start, and was appointed board chair when that position was created in 2016.

Mr. Oyler previously served as President and CEO of BioDuro, LLC, a drug discovery outsourcing company, from 2004 until it was that was acquired by Pharmaceutical Product Development Inc. in 2010. From 2002 to 2004, Mr. Oyler served as CEO of Galenea Corp., a biopharmaceutical company discovering novel therapies for central nervous system diseases. From 1997 to 2002, Mr. Oyler was the President of Telephia, Inc., a company he founded and ultimately sold to The Nielsen Company. From 1997 to 1998, Mr. Oyler was Co-Chief Executive Officer of Genta Incorporated (NASDAQ: GNTA), an oncology-focused biopharmaceutical company. He began his career as a management consultant at McKinsey & Company.

Mr. Oyler joined the Board of Directors of the Biotechnology Innovation Organization (BIO) in 2019 and is a member of its Health Section Governing Board. He received his B.S. mechanical engineering from Massachusetts Institute of Technology and MBA from Stanford University.